Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05915910 · ClinicalTrials.gov registry record
Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)
A clinical trial, sponsored by Sanguine Biosciences.
- Terminated
- Registry status
- 6
- Enrollment target
NCT05915910 is a clinical trial that was terminated before completion, run by Sanguine Biosciences. The registered enrollment target is 6 participants.
The verdict
NCT05915910 was terminated before completion, sponsored by Sanguine Biosciences.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The primary objective of this study is to collect whole blood from patients diagnosed with Glycogen storage disease type 1B, which will be used to support the investigation of potential therapies that address the genetic basis of this disease.
Interventions
- DIAGNOSTIC_TEST Specimen Donation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2023-04-27 |
| Est. Completion | 2024-03-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05915910
The ClinicalTrials.gov registry entry for NCT05915910 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanguine Biosciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Specimen Donation is the first listed.
NCT05915910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05915910 about?
NCT05915910 is a clinical study titled "Prospective Collection of Biospecimen in Pediatric Patients and Adult Guardians Diagnosed With Glycogen Storage Disease Type 1B (GSD1b)". The primary objective of this study is to collect whole blood from patients diagnosed with Glycogen storage disease type 1B, which will be used to support the investigation of potential therapies that address the genetic basis of this disease.
What is the current status of trial NCT05915910?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2023-04-27. Estimated completion is 2024-03-13.
What interventions are being tested in trial NCT05915910?
The interventions under investigation include: Specimen Donation (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05915910?
This trial is sponsored by Sanguine Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.